Advanced Medical Solutions Group plc: Acquisition of Sealantis
Winsford, UK, 31 January 2019: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces it has acquired Sealantis Limited ( “Sealantis”), a developer of an alginate-based tissue adhesive technology platform, for $US 25m (approximately £19m) in cash with royalties due until December 2027 on sales of any of its products that are currently in development.Overview of SealantisSealantis is an Israeli-based medical device company with a patent-protected alga-mimetic sealants technology platform with a wide range of potential surgical indications under developm...
Source: Medical Hemostat - February 1, 2019 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding
The U.S. Food and Drug Administration permitted marketing of Hemospray, a new device used to help control certain types of bleeding in the gastrointestinal (GI) tract.“The device provides an additional, non-surgical option for treating upper and lower GI bleeding in certain patients, and may help reduce the risk of death from a GI bleed for many patients,” said Binita Ashar, M.D., director, division of surgical devices, in the FDA’s Center for Devices and R adiological Health.GI bleeding can occur in the upper GI tract (esophagus, stomach or small intestine) or the lower GI tract (colon and rectum). Causes of GI blee...
Source: Medical Hemostat - September 23, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Cohera Medical Inc. ® Awarded Patent on its Biodegradable Sealant Technology
Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that the U.S. Patent and Trademark Office (USPTO) has issued the Company a notice of allowance on its patent application, titled “SILANE-CONTAINING MOISTURE-CURABLE TISSUE SEALANT”.The patent relates to a novel 100% synthetic sealant with several potential surgical applications. The sealant covered by the patent, Sylys ® Surgical Sealant, is highly elastic, and has good bonding strength to internal tissues. In addition, the sealant is easy to prepare and apply in the operating theatre and ...
Source: Medical Hemostat - April 25, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Baxter acquires surgical products
Baxter International Inc., a global medical products company, said Monday that it will acquire two hemostat and sealant products from Mallinckrodt.It will acquire Recothrom Thrombin topical, the first and only stand-alone recombinant thrombin, and Preveleak Surgical Sealant, which is used in vascular reconstruction." Uncontrolled intraoperative bleeding can lead to a wide variety of clinical and economic complications for patients and hospitals. As a leading provider of advanced hemostats and sealants, Deerfield-based Baxter is focused on continually identifying solutions to help meet surgeons ' varying needs, " said Wil B...
Source: Medical Hemostat - January 9, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Hemostasis Solution Controls Bleeding during Surgery
A novel handheld device delivers a powder based on collagen to help surgeons achieve hemostatic bleeding control during surgical procedures.The Biom ’Up (Saint-Priest, France) HemoBlast Bellows is a sterile delivery device that is preloaded with a dry, sterile powder made of highly purified porcine collagen, glucose, chondroitin sulfate, and thrombin. The hemostatic powder is applied to the source of the bleeding by squeezing the bellows. Once applied, the powdered collagen and glucose components start the coagulation process by absorbing blood, concentrating coagulation factors and platelets, and providing a surface for...
Source: Medical Hemostat - January 2, 2018 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
---
SAN JOSE, Calif.--(BUSINESS WIRE)--Starch Medical Inc. a privately held manufacturer and marketer of polysaccharide based hemostatic products for use in controlling bleeding in surgery and trauma applications has expanded its product portfolio with the launch of SuperClot ® Hemostat in Europe.Starch Medical received CE Approval earlier this year for SuperClot ® and will utilize their existing network of distribution partners along with new strategic partners to bring this innovative new polymer hemostat solution to surgical teams and hospitals throughout Europe. Next week Starch Medical will exhibit and hold distributor ...
Source: Medical Hemostat - November 8, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Gecko Biomedical receives CE Mark Approval for SETALUM ™ Sealant
Paris, France, September 11, 2017 – Gecko Biomedical (“Gecko”), a medical device company developing innovative polymers to support tissue reconstruction, announced today that it has received CE Mark approval for its SETALUM™ Sealant allowing the company to market its technology in Europe.The SETALUM ™ Sealant is a biocompatible, bioresorbable and on-demand activated sealant usable in wet and dynamic environments as an add-on to sutures during vascular surgery. The polymer is applied to tissue in-situ and activated using a proprietary light activation pen.The technology at the foundation of the SETALUM ™ Sealant...
Source: Medical Hemostat - October 25, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Scientists Develop Squirtable Glue That Seals Wounds In Seconds
A potentially life-saving surgical glue that is highly elastic and adhesive can quickly seal wounds in seconds without the need for common staples or sutures.The surgical glue, called MeTro, is a development from biomedical engineers at the University of Sydney and biomedical engineers from Harvard University.MeTro has a high elasticity that can seal wounds in body tissues that need to expand and contract continuously, like the lungs, heart and arteries. Wounds on these types of tissues are prone to re-opening after sealing with staples and sutures.The glue is also beneficial for wounds that are in hard-to-reach places tha...
Source: Medical Hemostat - October 25, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Snake venom is key ingredient in experimental drug for heart patients
An experimental antiplatelet drug has surprising bite. Based on a protein found in snake venom, the new drug prevented blood clotting in mice without causing excessive bleeding after an injury, according to research published Thursday in the journal Arteriosclerosis, Thrombosis and Vascular Biology. The drug has yet to be tested in humans.Bleeding is a common side effect in the current crop of available antiplatelet drugs, which are usually prescribed for heart patients to prevent blood cells, called platelets, from clumping together and forming clots. Depending on where they occur, clots can lead to a stroke or heart atta...
Source: Medical Hemostat - June 9, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
TissuGlu ® Surgical Adhesive enables drain-free recovery in patients undergoing DIEP flap breast reconstruction
RALEIGH, N.C., June 08, 2017 -- Outcomes of the SANA Gerresheim series demonstrated that effective donor-site flap closure with TissuGlu Surgical Adhesive is a viable alternative to post-surgical drains. Dr. Sonia Fertsch presented the series, which included 41 DIEP flap breast reconstructions, at the EURAPS Research Council Meeting in Pisa last month. The annual event allows young surgeons to present top research initiatives to an audience of plastic surgeons and researchers from around the world. During a DIEP flap reconstruction, blood vessels, skin and fat of the lower abdomen are removed and utilized to reco...
Source: Medical Hemostat - June 9, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Hemostatic agents market is estimated to reach USD 8,347.9 Million by 2022
Surgery is a foundational component of health-care systems. Over 51 million hospital-based surgical procedures are performed annually worldwide. The effective management of bleeding to achieve hemostasis during surgical procedures is essential to promote positive outcomes. As surgical procedures evolve to be more refined and noninvasive, the utilization of fast acting biologically and synthetically derived hemostats, encompassing fibrin sealants, flowable gelatins and adhesives, is becoming increasingly prevalent. Some of the parameters for choosing a hemostatic agent includes efficiency, type of surgery, patient condition...
Source: Medical Hemostat - June 2, 2017 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Fibrin Glue Market: Asia is expected to witness high growth rates in the next five years, 2021
Fibrin glue is a unique adhesion material used in surgeries for closure of wounds. Fibrin glues are mainly extracted from collective plasma and contain different amounts of purified and virally-inactivated human proteins. Fibrin glue is composed of two components, including fibrinogen and factor XIII. These concentrated ingredients interact with a solution of thrombin and calcium to form coagulum. As the thrombin and fibrinogen/factor XIII solution combine, a clot of a blood protein called fibrin develops in a few seconds, depending on the dilute form of thrombin is used. Some of the characteristics of fibrin glue include ...
Source: Medical Hemostat - November 19, 2016 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Mallinckrodt Diversifies Hospital Growth Portfolio, Acquiring Three Commercial-Stage, Global Specialty Hemostasis Brands From The Medicines Company
CHESTERFIELD, United Kingdom, Dec. 18, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it has entered into a purchase agreement with The Medicines Company (NASDAQ: MDCO) under which subsidiaries of Mallinckrodt plc will acquire a global portfolio of three commercial-stage topical hemostasis drugs – RECOTHROM® Thrombin topical (Recombinant), PreveLeak™ Surgical Sealant, and RAPLIXA™ (Fibrin Sealant) – for an initial payment of approximately $175 million, inclusive of existing inventory. Th...
Source: Medical Hemostat - December 19, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Most Don't Need'Bridging' When They Stop Warfarin Temporarily
In this study, Ortel ' s team randomly assigned patients to take either heparin or an inactive placebo during that time window. < /span > < br / > < span style= " color: #444444; font-family: Verdana, sans-serif; " > < br / > < /span > < span style= " color: #444444; font-family: Verdana, sans-serif; " > In the end, heparin showed no effect on blood-clot risk. Just 0.3 percent of treated patients developed a clot within a month of their procedure, versus 0.4 percent of patients given the placebo, the study found. < /span > < br / > < span style= " color: #444444; font-family: Verdana, sans-serif; " > < br / > < /span > < s...
Source: Medical Hemostat - August 26, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
Most Don't Need 'Bridging' When They Stop Warfarin Temporarily
In this study, Ortel's team randomly assigned patients to take either heparin or an inactive placebo during that time window.In the end, heparin showed no effect on blood-clot risk. Just 0.3 percent of treated patients developed a clot within a month of their procedure, versus 0.4 percent of patients given the placebo, the study found.On the other hand, heparin did boost the odds of serious bleeding. Just over 3 percent of patients developed "major" bleeding, compared with just over 1 percent of placebo patients, the study found.The findings suggest that bridging is unnecessary for most atrial fibrillation patients, Ortel ...
Source: Medical Hemostat - August 26, 2015 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs
